Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a buy rating to a hold rating in a research note published on Monday morning.
According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “
A number of other brokerages have also recently issued reports on ACRX. ValuEngine cut AcelRx Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, October 12th. HC Wainwright reissued a buy rating and set a $10.00 price objective on shares of AcelRx Pharmaceuticals in a report on Tuesday, October 3rd. Piper Jaffray Companies reissued a hold rating and set a $2.00 price objective on shares of AcelRx Pharmaceuticals in a report on Friday, October 13th. Roth Capital set a $8.00 price objective on AcelRx Pharmaceuticals and gave the company a buy rating in a report on Thursday, October 12th. Finally, Jefferies Group cut AcelRx Pharmaceuticals from a buy rating to a hold rating in a report on Friday, October 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus price target of $6.21.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by ($0.02). analysts predict that AcelRx Pharmaceuticals will post -1.06 earnings per share for the current fiscal year.
In other AcelRx Pharmaceuticals news, Director Mark G. Edwards purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 14th. The stock was acquired at an average cost of $1.90 per share, with a total value of $57,000.00. Following the completion of the acquisition, the director now directly owns 150,000 shares of the company’s stock, valued at approximately $285,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 28.10% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the stock. Geller Family Office Services LLC bought a new position in shares of AcelRx Pharmaceuticals in the third quarter valued at about $460,000. Perennial Advisors LLC acquired a new stake in AcelRx Pharmaceuticals in the third quarter worth about $138,000. Goldman Sachs Group Inc. acquired a new stake in AcelRx Pharmaceuticals in the second quarter worth about $530,000. Finally, Virtu KCG Holdings LLC increased its position in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after purchasing an additional 101,742 shares during the period. 13.70% of the stock is owned by institutional investors and hedge funds.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.